z-logo
open-access-imgOpen Access
Tubular epithelial C1orf54 mediates protection and recovery from acute kidney injury
Author(s) -
Xie Hongyang,
Wang Yaqiong,
Zhang Hang,
Fan Qin,
Dai Daopeng,
Zhuang Lingfang,
Tao Rong,
Chen Qiujing,
Shen Weifeng,
Lu Lin,
Ding Xiaoqiang,
Zhang Ruiyan,
Yan Xiaoxiang
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13765
Subject(s) - kidney , acute kidney injury , medicine , renal function , pi3k/akt/mtor pathway , pathology , apoptosis , cancer research , endocrinology , biology , biochemistry
Acute kidney injury (AKI) incidence among hospitalized patients is increasing steadily. Despite progress in prevention strategies and support measures, AKI remains correlated with high mortality, particularly among ICU patients, and no effective AKI therapy exists. Here, we investigated the function in kidney ischaemia‐reperfusion injury (IRI) of C1orf54, a newly identified protein encoded by an open reading frame on chromosome 1. C1orf54 expression was high in kidney and low in heart, liver, spleen, lung and skeletal muscle in healthy mice, and in the kidney, C1orf54 was expressed in tubular epithelial cells (TECs), but not in glomeruli. C1orf54 expression was markedly decreased on Day 1 after kidney IRI and then gradually recovered to baseline levels by Day 7. Notably, relative to wild‐type mice, C1orf54‐knockout mice exhibited impaired TEC proliferation and delayed recovery after kidney IRI, which led to deteriorated renal function and increased mortality. Conversely, adenovirus‐mediated C1orf54 overexpression promoted TEC proliferation and ameliorated kidney pathology, which resulted in accelerated renal repair and improved renal function. Mechanistically, C1orf54 was found to promote TEC proliferation through PI3K/AKT signalling. Thus, C1orf54 holds considerable potential as a therapeutic target in kidney IRI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here